TG Therapeutics (TGTX) said Tuesday that it expects Q4 Briumvi US net product revenue of $103.6 million.
The company said its cash position at the end of 2024 was $310 million.
TG Therapeutics said it expects 2025 total global revenue of $540 million, including Briumvi US net product revenue of $525 million. Analysts polled by Capital IQ are looking for total revenue of $537.8 million.
Shares of the company were up more than 5% in recent premarket activity.
Price: 29.16, Change: +1.49, Percent Change: +5.38
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。